Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial
- Authors
- Lee, Yong-Joon; Cho, Jae Young; You, Seng Chan; Lee, Yong-Ho; Yun, Kyeong Ho; Cho, Yun-Hyeong; Shin, Won-Yong; Im, Sang Wook; Kang, Woong Chol; Park, Yongwhi; Lee, Sung Yoon; Lee, Seung-Jun; Hong, Sung-Jin; Ahn, Chul-Min; Kim, Byeong-Keuk; Ko, Young-Guk; Choi, Donghoon; Hong, Myeong-Ki; Jang, Yangsoo; Kim, Jung-Sun
- Issue Date
- Mar-2023
- Publisher
- OXFORD UNIV PRESS
- Keywords
- Ezetimibe; Statin; Diabetes mellitus; Atherosclerotic cardiovascular disease
- Citation
- EUROPEAN HEART JOURNAL, v.44, no.11, pp.972 - 983
- Journal Title
- EUROPEAN HEART JOURNAL
- Volume
- 44
- Number
- 11
- Start Page
- 972
- End Page
- 983
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87407
- DOI
- 10.1093/eurheartj/ehac709
- ISSN
- 0195-668X
- Abstract
- Aims This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy vs. high-intensity statin monotherapy among patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD).Methods and results This was a pre-specified, stratified subgroup analysis of the DM cohort in the RACING trial. The primary outcome was a 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke. Among total patients, 1398 (37.0%) had DM at baseline. The incidence of the primary outcome was 10.0% and 11.3% among patients with DM randomized to ezetimibe combination therapy vs. high-intensity statin monotherapy (hazard ratio: 0.89; 95% confidence interval: 0.64-1.22; P = 0.460). Intolerance-related discontinuation or dose reduction of the study drug was observed in 5.2% and 8.7% of patients in each group, respectively (P = 0.014). LDL cholesterol levels < 70 mg/dL at 1, 2, and 3 years were observed in 81.0%, 83.1%, and 79.9% of patients in the ezetimibe combination therapy group, and 64.1%, 70.2%, and 66.8% of patients in the high-intensity statin monotherapy group (all P < 0.001). In the total population, no significant interactions were found between DM status and therapy regarding primary outcome, intolerance-related discontinuation or dose reduction, and the proportion of patients with LDL cholesterol levelsConclusion Ezetimibe combination therapy effects observed in the RACING trial population are preserved among patients with DM. This study supports moderate-intensity statin with ezetimibe combination therapy as a suitable alternative to high-intensity statins if the latter cannot be tolerated, or further reduction in LDL cholesterol is required among patients with DM and ASCVD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87407)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.